The overlooked trade-off in spine implant innovation

Advertisement

Spine surgeons can build increasingly sophisticated constructs to hold the spine together. But the ultimate success of a fusion still depends on something no implant can guarantee: whether the patient’s bone heals.

For Catherine Olinger, MD, that creates a race inside every spinal fusion. The hardware must withstand mechanical stress long enough for the bone to form a solid connection. If healing falls behind, even the strongest instrumentation can fail.

And as implant technology advances, Dr. Olinger believes the specialty risks overlooking the biological limitations that determine whether those innovations succeed. Her research focuses on developing biomaterials that promote stronger, more reliable spinal fusion while minimizing the potential harm that implants can cause to surrounding bone and tissue.

Dr. Olinger, a spine surgeon and clinical assistant professor of orthopedics and rehabilitation at  Iowa City-based University of Iowa Health Care, studies biomaterials, bone healing and hardware development. Her research explores a question with implications for implant manufacturers, hospitals and surgeons alike: Are increasingly sophisticated devices solving the problems that matter most for long-term outcomes?

When stronger is not necessarily better

The materials used in spinal instrumentation have become increasingly sophisticated, offering surgeons new options for constructing stable fusions. But Dr. Olinger cautions that greater strength and rigidity do not automatically translate into better results.

Her laboratory investigates the biomechanical properties of materials such as titanium and cobalt-chromium, including how differences in stiffness affect the relationship between implants and surrounding bone.

A more rigid construct may provide substantial mechanical support while also altering how forces are transferred through the spine. That raises questions about stress shielding, the bone-implant interface and the potential for hardware complications.

“There’s a gentle balance between stiffness and rigidity,” she said.

Those questions become particularly important in patients with osteoporosis, whose compromised bone quality can complicate fixation and healing. Dr. Olinger believes manufacturers and researchers must consider not only what a stronger implant can accomplish, but whether the biological environment can support it.

“Just because you can do it doesn’t mean you should,” she said. Her concern is not with technological progress but with adopting new materials before fully understanding the trade-offs they introduce.

Healing problem begins before surgery

For Dr. Olinger, improving fusion outcomes requires looking beyond the operating room. At Iowa, patients with bone health concerns can undergo evaluations involving bone density, nutritional status and laboratory testing, with endocrinology specialists helping identify opportunities for optimization.

The team also examines osteosarcopenia, the combination of poor bone quality and reduced muscle mass, which can complicate recovery in vulnerable patients.

For those at greater risk, treatment may include preoperative rehabilitation, nutritional support and interventions intended to improve bone health. Dr. Olinger is particularly attentive to patients taking GLP-1 medications. Although weight loss can offer health benefits, she worries that reductions in body mass may sometimes be accompanied by muscle loss, leaving patients less physically prepared for major surgery.

A lower body mass index, in other words, does not necessarily tell the whole story. The same attention extends to the materials placed around the fusion site. Depending on patient risk, surgeons may use bone morphogenetic proteins, graft extenders and other biologics to support bone formation.

Dr. Olinger sees these decisions as interconnected. The effectiveness of a graft material cannot be separated entirely from the patient’s nutritional status, metabolic health and underlying bone quality.

The objective is to build a stronger construct and give it a better chance of becoming unnecessary as the patient’s own bone heals.

Where innovation meets the business of spine surgery

Developing better biomaterials is only part of the challenge. Making them accessible and determining which are worth their cost presents another.

“The challenges are industrial,” Dr. Olinger said. 

Medical device companies invest in research, develop proprietary products and seek returns on those investments. Dr. Olinger values industry partnerships and recognizes their role in advancing surgical care. But she believes surgeons need more independent evidence to distinguish products that meaningfully improve outcomes from those whose advantages remain uncertain.

Her laboratory evaluates different biologic materials, including bone graft extenders, with an emphasis on comparative research that is not designed to promote a particular manufacturer.

She hopes the next decade brings greater standardization in how biomaterials are investigated, allowing surgeons to compare their performance and costs more reliably.

That matters especially for physicians practicing outside major academic centers, who may have fewer resources to independently assess emerging technologies.

Dr. Olinger does not view industry involvement as inherently problematic. Rather, she argues that commercial incentives make rigorous, transparent evaluation essential. The goal is to preserve innovation while ensuring that clinical decisions are driven by evidence rather than marketing or financial relationships.

A less expensive path to better fusion?

Among the advances Dr. Olinger finds most promising are shelf-stable bone graft extenders, which could eventually support fusion with less reliance on donor-derived materials requiring specialized storage and processing.

She believes these developments could lower costs and expand access, particularly in regions such as South America and Southeast Asia, where surgeons may lack the bone banks and resources available at major U.S. institutions.

But affordability cannot come at the expense of successful fusion. Dr. Olinger hopes advances in biomaterials will improve bone healing while reducing dependence on costly graft products.

“My hope would be that in the next 10 or 15 years, we’re increasing our fusion rates while decreasing our dependence on allogeneic bone grafts,” she said.

For her, the next breakthrough in spinal fusion may depend less on building stronger implants than on ensuring the patient’s biology can support them.

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Spine

Advertisement